Sava Infond d.o.o. Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sava Infond d.o.o. acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,420 shares of the specialty pharmaceutical company’s stock, valued at approximately $421,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Cinctive Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $14,277,000. Pacer Advisors Inc. boosted its stake in Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after acquiring an additional 115,102 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares during the last quarter. GW&K Investment Management LLC grew its stake in shares of Jazz Pharmaceuticals by 26.6% during the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after acquiring an additional 97,589 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock worth $13,800,000 after purchasing an additional 93,422 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Down 3.4 %

Shares of NASDAQ:JAZZ opened at $126.40 on Friday. The firm’s 50-day moving average is $132.27 and its two-hundred day moving average is $122.32. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The firm has a market capitalization of $7.68 billion, a PE ratio of 17.80, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,022,825 in the last ninety days. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Barclays reiterated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.